Actinium Pharmaceuticals Inc (NYSEAMERICAN:ATNM) saw a significant growth in short interest in the month of December. As of December 15th, there was short interest totalling 2,269,284 shares, a growth of 21.6% from the November 30th total of 1,866,304 shares. Approximately 3.0% of the shares of the company are sold short. Based on an average daily volume of 971,311 shares, the days-to-cover ratio is currently 2.3 days.
Several research analysts have recently commented on ATNM shares. Zacks Investment Research raised shares of Actinium Pharmaceuticals from a “hold” rating to a “buy” rating and set a $0.75 target price on the stock in a report on Monday. Maxim Group set a $3.00 target price on shares of Actinium Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, December 12th. B. Riley set a $3.00 target price on shares of Actinium Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, December 12th. HC Wainwright reiterated a “buy” rating and set a $6.00 price target on shares of Actinium Pharmaceuticals in a research report on Monday, October 23rd. Finally, Roth Capital reiterated a “buy” rating and set a $6.00 price target on shares of Actinium Pharmaceuticals in a research report on Monday, October 23rd. Five investment analysts have rated the stock with a buy rating, The company presently has an average rating of “Buy” and a consensus target price of $3.75.
Actinium Pharmaceuticals (NYSEAMERICAN ATNM) traded up $0.01 during midday trading on Wednesday, hitting $0.70. 1,337,699 shares of the company traded hands, compared to its average volume of 717,340. The firm has a market cap of $54.34, a price-to-earnings ratio of -1.49 and a beta of 41.36. Actinium Pharmaceuticals has a twelve month low of $0.54 and a twelve month high of $1.72.
Actinium Pharmaceuticals, Inc (Actinium) is a clinical-stage biopharmaceutical company engaged in developing cancer treatments. The Company is engaged in developing therapies for diseases using its alpha particle immunotherapy platform and other related technologies. The Company’s products include Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), and Iomab-B, an antibody-drug construct containing iodine 131 (I-131).
What are top analysts saying about Actinium Pharmaceuticals? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Actinium Pharmaceuticals and related companies.